目的 探讨Yes相关蛋白(YAP)在子宫内膜癌中的表达及临床意义。方法 收集2018年9月至2019年12月在山西医科大学第一医院就诊并行全面分期手术的子宫内膜样腺癌病例共56例,年龄43～69岁(中位年龄为54岁),术前均未接受放、化疗且不合并其他系统肿瘤。对病理组织库中已行取材、石蜡包埋处理的对应病例癌、癌旁组织蜡块进行IHC法(切片、制片、一抗孵育、二抗孵育、脱水、封片)检测YAP表达情况,并分别计算高、低表达例数。比较子宫内膜样腺癌组织及正常癌旁组织YAP的表达。采用免疫组化法比较其表达与各临床病理学参数的关系,运用SPSS 22.0进行统计学分析,探讨YAP表达与各临床病理学特征之间的关系。结果 YAP主要表达在细胞核及胞浆中,且在癌组织中的表达明显高于癌旁组织,与组织学分级、手术病理分期、肌层浸润深度相关(P＜0.05)。结论 YAP与子宫内膜样腺癌的发生发展有关,可能作为临床治疗的新靶点。
Abstract
Objective To investigate the expression and clinical significance of Yes associated protein(YAP) in endometrial carcinoma. Methods A total of 56 patients with endometrioid adenocarcinoma who underwent comprehensive staging surgery in the First Hospital of Shanxi Medical University from September 2018 to December 2019 were collected. The ages ranged 43-69 years old(median age, 54 years). None of them received radiotherapy or chemotherapy before surgery and were not complicated with other systemic tumors. Immunohistochemistry(IHC) was performed on paraffin-embedded tissue blocks of corresponding cases in the pathological tissue bank to detect the expression of YAP, and the numbers of cases with high and low expression were calculated, respectively. The expression of YAP in endometrial adenocarcinoma tissue and normal adjacent tissue was compared. The relationship between its expression and various clinicopathological parameters was compared using immunohistochemistry, and statistical analysis was performed using SPSS 22.0 to explore the relationship between YAP expression and various clinicopathological features. Results YAP was mainly expressed in the nucleus and cytoplasm, and its expression in cancer tissues was significantly higher than that in adjacent tissues, which was correlated with histological grade, surgical pathological staging, and depth of muscle infiltration(P<0.05). Conclusion YAP is associated with the occurrence and development of endometrial adenocarcinoma and may serve as a new target for clinical treatment.
关键词
YAP /
子宫内膜样腺癌 /
Hippo信号通路
{{custom_keyword}} /
Key words
YAP /
endometrial adenocarcinoma /
hippo signaling pathway
{{custom_keyword}} /
中图分类号：
R71
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Ferlay J,Colombet M,Soerjomataram I,et al.Estimating the global cancer incidence and mortality in 2018:GLOBOCAN sources and methods.Int J Cancer,2019,144:1941-1953.
2 王婷婷,李忠华,李慧峰,等.非小细胞肺癌中YAP1、SRPX2的表达与微血管密度及预后的相关性分析.临床与实验病理学杂志,2020,36:264-269.
3 Fu M,Hu Y,Lan T,et al.The Hipposignalling pathway and its implications in human health and diseases.Signal Transduct Target Ther,2022,7:376.
4 Piccolo S,Panciera T,Contessotto P,et al.YAP/TAZ as master regulators in cancer:modulation,function and therapeutic approaches.Nat Cancer,2023,4:9-26.
5 Zheng L,Du J,Ge F,et al.Thecalcimimetic agent cinacalcet inhibits hepatocellular carcinoma via YAP/TAZ suppression.Pharmazie,2021,76:511-514.
6 Kandoth C,Schultz N,Cherniack AD,et al.Cancer Genome Atlas Research N Intergrated genomic characterization of endometrial carcinoma.Nature,2013,497:67-73.
7 Pecorelli S.Revised FIGO staging for carcinoma of the vulva,cervix,and endometrium.Int J Gynaecol Obstet,2019,105:103-104.
8 宋露露.子宫内膜样癌及其前驱病变YAP1、PTEN、eIF4E和CyclinD1的表达及意义.天津医科大学,2018.
9 Siegel RL,Miller KD,Wagle NS,et al.Cancer statistics,2023.CA Cancer J Clin,2023,73:17-48.
10 Morice P,Leary A,Creutzberg C,et al.Endometrial cancer.Lancet,2016,387:1094-1108.
11 Makker V,Mackay H,Ray-Coquard I,et al.Endometrial cancer.Nat Rev Dis Primers,2021,7:88.
12 Lewin SN,Herzog TJ,Barrena Medel NI,et al.Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer.Obstet Gynecol,2010,116:1141-1149.
13 Siegel RL,Miller KD,Fuchs HE,et al.Cancer Statistics,2021.CA Cancer J Clin,2021,71:7-33.
14 徐婉秋,许晓航,刘畅,等.Hippo信号通路在口腔鳞状细胞癌中的研究进展.中华口腔医学杂志,2021,56:221-225.
15 Zhou Q,Bauden M,Andersson R,et al.YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling.J Transl Med,2020,18:77.
16 祝景伟,佟经伟,许培权.Hippo信号通路中TAZ、YAP在三阴性乳腺癌中的表达及意义.陕西医学杂志,2020,49:940-943,968.
17 Wang D,He J,Dong J,et al.The HIPPO pathway in gynecological malignancies.Am J Cancer Res,2020,10:610-629.
18 Boopathy G,Hong W.Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis.Front Cell Dev Biol,2019,7:49.
19 荆丽红.β-catenin、YAP1、TBX5 和 Survivn 在子宫内膜癌中的表达和意义.天津医科大学,2016:1-26.
20 Cheng Y,Huang H,Han Y,et al.Expression of YAP in endometrial carcinoma tissues and its effect on epithelial to mesenchymal transition.Transl Cancer Res,2020,9:7248-7258.
21 Wang J,Song T,Zhou S,et al.YAP promotes the malignancy of endometrial cancer cells via regulation of IL-6 and IL-11.Mol Med,2019,25:32.
22 Yang J,Song DH,Kim CH,et al.Expression of the Hippo Pathway Core Components in Endometrial Cancer and Its Association with Clinicopathologic Features.Diagnostics(Basel),2022,12:2973.
23 程允.YAP 基因在子宫内膜癌中的表达及其与上皮间质转化关系的研究.安徽医科大学,2018:1-27.
24 Wang J,Song T,ZhouS,et al.YAP promotes the malignancy of endometrial cancer cells via regulation of IL-6 and IL-11.Mol Med,2019,25:32.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
山西省重点研发计划(社会发展方面,201803D31103)
{{custom_fund}}
PDF(432 KB)
